News News

2026/10/01

Seizing the AI ​​Opportunity in the Healthcare Sector!

From Economic Daily News, Taipei, 2026/09/30 16:31:19

A cross-industry collaboration is on the horizon for Taiwan's biotechnology and artificial intelligence (AI) sectors! SG Biomedical announced today that it plans to partner with Accelerate Private Machine Intelligence Company (APMIC) and collaborate with major domestic medical institutions to develop a "medical-domain AI large language model." This initiative aims not only to challenge the dominance of Western tech giants in the field of generative AI but also to unlock a vast, untapped market for precision medicine and smart healthcare.

Addressing the global trend of "Sovereign AI" to safeguard core healthcare data and value: As digital technology advances rapidly worldwide, nations and specific industries are placing increasing emphasis on information security, geopolitics, and cultural localization—making "Sovereign AI" one of the most significant market trends today.


In the healthcare sector, medical records, genetic data, and clinical expertise constitute highly sensitive, core assets of national strategic importance. Conventional, general-purpose large language models—largely developed by major American or Chinese technology firms—not only pose legal risks related to data leakage and privacy compliance, but also frequently encounter bottlenecks in clinical application due to a lack of deep understanding regarding Asian populations, localized medical terminology, and specific cultural contexts.

SG Biomedical has partnered with APMIC to develop an AI language model tailored specifically for the healthcare sector. By prioritizing data localization, model autonomy, and on-premises regulatory compliance, this initiative aims to fundamentally address the critical issue of medical data sovereignty. With its high precision and robust security, the model is poised to become an indispensable core asset for healthcare institutions undergoing digital transformation, ultimately fostering a multi-billion-dollar ecosystem for smart healthcare applications.

This collaborative project aims to leverage strengths across three key areas: biomedical distribution channels, clinical data, and AI technology. SG Biomedical, drawing on its extensive, long-standing distribution network in the field of plasma medicine, will oversee the overall commercialization strategy and market outreach. APMIC will contribute its expertise in building and fine-tuning proprietary AI models, providing robust AI algorithmic architectures, high-efficiency computational optimization, and natural language processing capabilities. These efforts will be integrated with de-identified clinical big data from major Taiwanese medical institutions, alongside knowledge bases curated by professional medical experts.

This model has an exceptionally wide range of potential applications. Future plans include its full-scale integration into areas such as the generation of intelligent medical records, cross-departmental clinical decision support, data screening for new drug development, and automated patient-provider communication systems. Such implementation promises to significantly alleviate the administrative burden on frontline healthcare professionals, enhance the precision of medical diagnoses, and reduce patient wait times—offering immense commercial value. According to projections from international market research firms, the global market for smart healthcare and generative AI-driven medical applications is set to experience explosive compound annual growth in the coming years.

SG Biomedical and APMIC have stated that their collaboration on AI models tailored for the medical sector is merely the first step. They plan to use Taiwan as a pilot site for this highly replicable and locally compliant system, with the ultimate goal of expanding it into healthcare ecosystems throughout the Asia-Pacific region—thereby steering Asia's smart healthcare industry toward a significant new milestone.

《About SG Biomedical》

Guided by the corporate vision of "innovating biotechnological and medical device technologies to foster a high-quality, healthy life," SG Biomedical is committed to becoming a leader in the field of innovative medical devices. The company focuses on the development of products related to "plasma technology and smart healthcare" as well as the R&D of innovative medical devices, with a strategic presence in the Asian healthcare market.

《About APMIC》

Accelerate Private Machine Intelligence Company (APMIC) specializes in building bespoke AI "brains" for enterprises. Through precise model fine-tuning, on-premises or hybrid deployment, and deep system integration, APMIC helps organizations establish secure, controllable, and cost-effective AI infrastructure—transforming knowledge into actionable decisions and operational intelligence.

※ You are welcome to share the article link by "reposting" or "sharing"; please do not copy and paste the article content without authorization.
Go To Top